Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Simulations Plus' (SLP) Q1 results were affected by lower revenues in Software business segment.

Simulations Plus (SLP) Q1 Earnings & Revenues Miss Estimates

Simulations Plus, Inc. (NASDAQ:SLP ) Q1 2023 Results Conference Call January 4, 2023 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Dane Leone - Raymond James François Brisebois - Oppenheimer Mitra Ramgopal - Sidoti Operator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q1 2023 Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of -50% and 3.79%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Q1 Earnings and Revenues Miss Estimates

LANCASTER, Calif.--( BUSINESS WIRE )--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter of fiscal 2023, ended November 30, 2022.

Simulations Plus Reports First Quarter Fiscal 2023 Financial Results

FlexShares STOXX US ESG Impact Index Fund

LANCASTER, Calif.--( BUSINESS WIRE )--Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023.

Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call

Today, we take our first look at Simulations Plus, Inc., which supplies modeling software and services to the Biotech and Pharma industries. The stock is trading near 52-week lows despites delivering solid profit and revenue growth.

Simulations Plus: In The Spotlight

Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship Program

Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code

Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products

Simulations Plus, Inc. (NASDAQ:SLP ) Q4 2022 Earnings Conference Call October 26, 2022 5:00 PM ET Company Participants Brian Siegel – Hayden IR Shawn O'Connor – Chief Executive Officer Will Frederick – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum François Brisebois – Oppenheimer & Co. Dane Leone – Raymond James Operator Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q4 2022 Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of -22.22% and 6.12%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Lags Q4 Earnings Estimates

Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results

Simulations Plus Announces Cash Dividend

Simulations Plus Releases GastroPlus® Version 9.8.3

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 4th quarter and fiscal year 2022 financial results on Oct. 26, 2022, with a webcast at 5pm ET.

Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call

Activision Blizzard

Change Healthcare Inc

Citrix Systems

CYREN

Sunrise New Energy Co. Ltd

Powerbridge Technologies Co Ltd

Qualys

SurgePays

Sierra Wireless

The packaged software industry includes companies that offer multiple software programs bundled together to make a complete set.

These Are The 10 Best-Performing Packaged Software Companies In 2022

Simulations Plus (SLP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 13.7% in 4 Weeks, Here's Why the Trend Might Reverse for Simulations Plus (SLP)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will be presenting at Sidoti's virtual Fall Small Cap Investor Conference on Thursday, Sept. 22, at 10:45 a.m. ET.

Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be presenting at Baird's 2022 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Sept. 14 at 2pm ET.

Simulations Plus to Present at Baird 2022 Global Healthcare Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ILDsym version 1A, QSP software to accelerate the development of therapies to halt or reverse interstitial lung disease.

Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today a new collaboration to enhance ADMET Predictor, its preeminent property prediction platform for drug discovery.

Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus MonolixSuite modeling & simulation software was featured in several scientific posters at PAGE 2022 in Ljubljana, Slovenia.

Simulations Plus Presented New Scientific Developments at PAGE 2022

Does Simulations Plus (SLP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Simulations Plus (SLP) is a Great Momentum Stock to Buy

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus continues its 25th anniversary celebration with a $25,000 donation to St. Jude Children's Research Hospital.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus launches its Concierge Program to facilitate value-added strategic partnerships with customers to accelerate drug development.

News for Simulations Plus Stock (SLP)